Author

Nervin Lawendy 1

1 Pfizer Inc,Collegeville,United States

An update on the analysis of non-melanoma skin cancer in the tofacitinib ulcerative colitis programme

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

Laboratory parameters related to monitoring in patients with ulcerative colitis treated with tofacitinib for up to 3 years in the OCTAVE open-label, long-term extension study

Gil Y. Melmed, Shannon Chang, nicole kulisek, Haiyun Fan, Nervin Lawendy, Eric Maller, Arif Soonasra, Peter Irving

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

Jean-Frederic Colombel, Walter Reinisch, Mark T. Osterman, Andrew J. Thorpe, Chudy I. Nduaka, Haiying Zhang, Nervin Lawendy, Gary S. Friedman, Chinyu Su

Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme

William Sandborn, Julian Panés, Bruce E. Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto, Daniel Quirk, Silvio Danese

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES

Uma Mahadevan, Daniel C. Baumgart, Marla C. Dubinsky, Nervin Lawendy, Gary S. Friedman, Gauree G. Konijeti, Hans Peter Gröchenig, Thomas V Jones, Amy Marren, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

INTEGRATED SAFETY ANALYSES OF TOFACITINIB IN ULCERATIVE COLITIS CLINICAL TRIALS

William Sandborn, Julian Panés, Geert R. D'Haens, Bruce E. Sands, Chinyu Su, Michele Moscariello, Thomas V Jones, Ron Pedersen, Gary S. Friedman, Nervin Lawendy, Gary Chan

Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: an interim analysis of an open-label, long-term extension study with up to 5.5 years of treatment

Gary R. Lichtenstein, Edward V. Loftus Jr., Arif Soonasra, Nervin Lawendy, Gary Chan, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Stuart Bloom

Predictors of delayed response to tofacitinib: results of the octave open study for delayed responders

Miguel Regueiro, Jami A. Kinnucan, Ryan Ungaro, Daniel Quirk, Chinyu Su, Nervin Lawendy, Haiyun Fan, Deborah.A Woodworth, Markus F. Neurath

TIME TO LOSS OF EFFICACY FOLLOWING TOFACITINIB INTERRUPTION IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM OCTAVE SUSTAIN

Marla C. Dubinsky, Kofi Clarke, Jochen G. Klaus, Yoram Bouhnik, Arif Soonasra, Andrew J. Thorpe, Haiying Zhang, Gary S. Friedman, Deborah A. Woodworth, Nervin Lawendy, Chinyu Su

Item 1 - 10 / 15
1
2